CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform
NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, has closed its Series B financing round led by Kurma Growth Opportunities Fund. The proceeds of CHF 79 million (EUR 84 million) will be used to advance the clinical development of NUCLIDIUM’s Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications and expand its global production network.
NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy and complex manufacturing. Diagnostic results from initial clinical trials in these indications show superior lesion detection and higher tumor-to-background ratios compared with clinically approved tracers.
Initial data were recently presented at SNMMI 2025 by Dr. Gary Ulaner, highlighting a favorable safety profile and potentially improved imaging performance of 61Cu-NuriPro™compared to current PET imaging standards, suggesting strong clinical promise and broader potential for 61Cu/67Cu theranostic pairing. Early therapeutic data from the two lead compounds, NuriPro™ and TraceNET™, show strong tumor-to-background ratios in metastatic prostate cancer and neuroendocrine tumors including breast cancer.
The fresh capital injection will allow NUCLIDIUM to continue expanding its worldwide production and manufacturing network for diagnostics and therapeutics, growing its international team, and strengthening strategic collaborations with hospitals and academic centers, initially across Europe and North America.
“This significant Series B financing reflects the confidence of our investors in NUCLIDIUM’s vision and the transformative potential for the diagnostic and therapeutic industry in oncology and nuclear medicine,” said Tony Rosenberg, Chairman of the NUCLIDIUM Board. “With this backing, we are positioned to accelerate clinical development, broaden patient access globally, and reinforce our commitment to innovation in precision oncology. I am delighted to welcome our new Board and advisory members, whose deep expertise will further strengthen NUCLIDIUM’s leadership in radiopharmaceuticals.”
New members on the board
Alongside lead investor, Kurma Growth Opportunities Fund, the round saw the participation of Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors.
In conjunction with the financing round, Daniel Parera, Partner at Kurma Partners, Regina Hodits, Managing Director at Angelini Ventures, and Liliana Nordbakk, Partner Life Sciences at Neva SGR, will join NUCLIDIUM’s Board of Directors.
(Press release/RAN)